Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 28;3(2):176-186.
doi: 10.1016/j.jacbts.2018.01.013. eCollection 2018 Apr.

Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension

Lauren Brash  1 , Gareth D Barnes  2 , Melanie J Brewis  1 , A Colin Church  1 , Simon J Gibbs  2 , Luke S G E Howard  2 , Geeshath Jayasekera  1 , Martin K Johnson  1 , Neil McGlinchey  1 , Joelle Onorato  3 , Joanne Simpson  1 , Colin Stirrat  4 , Stephen Thomson  1 , Geoffrey Watson  2 , Martin R Wilkins  2 , Carrie Xu  3 , David J Welsh  1 , David E Newby  4 , Andrew J Peacock  1
Affiliations

Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension

Lauren Brash et al. JACC Basic Transl Sci. .

Abstract

Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170).

Keywords: APJ; CO, cardiac output; FA, formic acid; NO, nitric oxide; PAEC, pulmonary artery endothelial cells; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase-5; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance; apelin; human; pulmonary arterial hypertension.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Hemodynamic Changes During Apelin Infusion in Patients With PAH Hemodynamic changes during infusion of (Pyr1)apelin-13 (solid squares) or matched saline placebo (open squares) in patients with pulmonary arterial hypertension (PAH) in pulmonary vascular resistance (PVR), cardiac output, mean pulmonary artery pressure (mPAP), heart rate, systemic vascular resistance (SVR), and mean arterial pressure (MAP). Data are reported as mean ± SEM. *p = 0.0089, **p = 0.002, ***p < 0.0006, §p = 0.0001, and #p ≤ 0.0001 2-way analysis of variance with post hoc Bonferroni tests. bpm = beats per minute.
Figure 2
Figure 2
Effect of Apelin and Exercise on PVR Pulmonary vascular resistance during infusion of (Pyr1)apelin-13 or matched saline placebo in patients with pulmonary arterial hypertension while undergoing exercise protocol. A zero reflects resting measurements, raise reflects measurements taken with legs raised in ergometers pedals at rest, then further measurements at 20% and 40% of previous erect maximal cardiopulmonary exercise test performance. Data are reported as mean ± SEM. *p = 0.019, 2-way analysis of variance with post hoc Bonferroni tests. PVR = pulmonary vascular resistance.
Figure 3
Figure 3
Patients With or Without PDE5 Inhibitor Treatment Hemodynamic changes during infusion of (Pyr1)apelin-13 (solid squares) or matched saline placebo (open squares) in patients with pulmonary arterial hypertension who are (A) on treatment with PDE5 inhibitors or (B) not on treatment with PDE5 inhibitors. Data are reported as mean ± SEM. *p = 0.049, **p = 0.0127, *** p = 0.0042, §p = 0.0039, §§p = 0.0017, #p = 0.0011, ##p = 0.0003, 2-way analysis of variance with post hoc Bonferroni tests. Abbreviations as in Figure 1.
See this image and copyright information in PMC

References

    1. Morrell N.W., Adnot S., Archer S.L. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S20–S31. - PMC - PubMed
    1. NHS Digital. Fifth Annual Report: Key Findings From the National Audit of Pulmonary Hypertension of the United Kingdom, Channel Islands, Gibraltar and Isle of Man. Health and Social Care Information Centre; Leeds, UK: 2015. pp. 1–38.
    1. Tatemoto K., Hosoya M., Habata Y. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471–476. - PubMed
    1. Kleinz M.J., Skepper J.N., Davenport A.P. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233–240. - PubMed
    1. Salcedo A., Garijo J., Monge L. Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. Regul Pept. 2007;144:50–55. - PubMed

Associated data